Document is current
Any future updates will be listed below
-
Authors
Rathnasinghe, Raveen https://orcid.org/0000-0002-1260-2493
Jangra, Sonia
Ye, Chengjin https://orcid.org/0000-0002-1934-9494
Cupic, Anastasija https://orcid.org/0000-0002-1291-1042
Singh, Gagandeep https://orcid.org/0000-0003-3260-2631
Martínez-Romero, Carles https://orcid.org/0000-0001-8888-7715
Mulder, Lubbertus C. F.
Kehrer, Thomas
Yildiz, Soner
Choi, Angela
Yeung, Stephen T.
Mena, Ignacio https://orcid.org/0000-0001-5464-7086
Gillespie, Virginia https://orcid.org/0000-0003-3387-0021
De Vrieze, Jana
Aslam, Sadaf
Stadlbauer, Daniel https://orcid.org/0000-0001-6792-7650
Meekins, David A.
McDowell, Chester D.
Balaraman, Velmurugan
Corley, Michael J.
Richt, Juergen A. https://orcid.org/0000-0001-7308-5672
De Geest, Bruno G.
Miorin, Lisa
,
Kleiner, Giulio
Saksena, Miti
Srivastava, Komal
Gleason, Charles R.
Bermúdez-González, Maria C.
Beach, Katherine F.
Russo, Kayla T.
Sominsky, Levy A.
Ferreri, Emily D.
Chernet, Rachel L.
Eaker, Lily Q.
Salimbangon, Ashley-Beathrese T.
Jurczyszak, Denise
Alshammary, Hala
Mendez, Wanni A.
Amoako, Angela A.
Fabre, Shelcie
Awawda, Mahmoud H.
Shin, Amber S.
Krammer, Florian https://orcid.org/0000-0003-4121-776X
Martinez-Sobrido, Luis https://orcid.org/0000-0001-7084-0804
Simon, Viviana https://orcid.org/0000-0002-6416-5096
García-Sastre, Adolfo https://orcid.org/0000-0002-6551-1827
Schotsaert, Michael https://orcid.org/0000-0003-3156-3132
- License Information
-
More Information
Article History
Received: 14 January 2021
Accepted: 13 May 2022
First Online: 7 July 2022
Competing interests
: The A.G.-S. laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, ImmunityBio, and Nanocomposix. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Pagoda, Accurius, and Esperovax. M.S. has licensed SARS-CoV-2 serological assays to commercial entities and has filed for patent protection for serological assays as well as SARS-CoV-2 vaccines. F.K. is listed as inventors on the pending patent applications. The F.K. laboratory has received research support from GSK, Dynavax, and Pfizer. F.K. has in the past received consulting fees from Curevac, Merck, Pfizer, and Seqirus. The J.A.R. laboratory received support from Tonix Pharmaceuticals, Xing Technologies and Zoetis, outside of the reported work. J.A.R. is inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections, owned by Kansas State University, KS, or the Icahn School of Medicine at Mount Sinai, New York. A provisional patent application on a “A novel 4 Amino Acid Insertion into the Spike Protein of SARS-CoV-2” was submitted by KSU in July 2020 with C.D.M., D.A.M., and J.A.R. listed as inventors. The remaining authors declare no competing interests.
